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Abstract
Background: MicroRNAs (miRNAs) can play important roles in inflammation and
infection, which are common manifestations of acute respiratory distress syndrome
(ARDS). We assessed if whole blood miRNAs were potential diagnostic biomarkers for
human ARDS.
Methods: This nested case-control study (N = 530) examined a cohort of ARDS
patients and critically ill at-risk controls. Whole blood miRNA profiles and logistic
regression analyses identified miRNAs correlated with ARDS. Stratification analysis
also assessed selected miRNA markers for their role in sepsis and pneumonia
associated with ARDS. Receiver operating characteristic (ROC) analysis evaluated
miRNA diagnostic performance, along with Lung Injury Prediction Score (LIPS).
Results: Statistical analyses were performed on 294 miRNAs, selected from 754
miRNAs after quality control screening. Logistic regression identified 22 miRNAs from
a 156-patient discovery cohort as potential risk or protective markers of ARDS. Three
miRNAs—miR-181a, miR-92a, and miR-424—from the discovery cohort remained
significantly associated with ARDS in a 373-patient independent validation cohort
(FDR q < 0.05) and meta-analysis (p < 0.001). ROC analyses demonstrated a LIPS
baseline area-under-the-curve (AUC) value of ARDS of 0.708 (95% CI 0.651–0.766).
Addition of miR-181a, miR-92a, and miR-424 to LIPS increased baseline AUC to 0.723
(95% CI 0.667–0.778), with a relative integrated discrimination improvement of 2.40
(p = 0.005) and a category-free net reclassification index of 27.21% (p = 0.01).
Conclusions: miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424
is a protective biomarker. Addition of these miRNAs to LIPS can improve the risk
estimate for ARDS.
Keywords: ARDS, MicroRNA, LIPS, Whole blood
Background
Acute respiratory distress syndrome (ARDS) is a complex syndrome occurring in crit-
ically ill patients and is characterized as acute inflammation and infection caused by
direct and indirect injury to the lung. ARDS affects approximately 200,000 people an-
nually in the USA, carries a mortality rate of 40%, and is a major cause of intensive
care unit (ICU) morbidity and mortality worldwide [1]. ARDS is mainly initiated by
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neutrophils accumulation and activation in the lungs, such cells can release inflamma-
tory mediators and cytokines to damage pulmonary tissues [2, 3].
Importantly, the complex etiology and lack of reliable biomarkers have complicated
ARDS diagnosis and treatment. Many protein-based biomarkers have been identified
from plasma [4], but none have been translated to clinical diagnostic routines. More
comprehensive study designs are needed to identify new mediators for ARDS patho-
genic mechanisms [5]. Further, no previous studies have evaluated the potential or per-
formance of whole blood microRNAs (miRNAs) to diagnose ARDS.
miRNAs, a group of small non-coding RNAs, regulate gene expression by binding to
specific target sites on messenger RNA to either repress or degrade targets. Previous
studies have discovered important roles for miRNAs in many disorders, including in-
flammation and infection [6, 7]. Thus, miRNA expression patterns may be able to serve
as diagnostic biomarkers for better disease detection [8, 9]. Studies have suggested miR-
NAs are involved in ARDS development. In a rat model of ARDS, miRNA profiling of
lung tissue demonstrated altered expression of multiple miRNAs compared to control
tissues [10]. We recently demonstrated that whole blood miRNAs can be potentially
valuable for predicting ARDS 28-day mortality due to their related function in multiple
organ failure (MOF), which is a primary risk factor of ARDS patient mortality. Indeed,
a miRNA panel is comparable to APACHE III in mortality prediction ability [11].
Yet, to date, no study has tested whether whole blood miRNAs may serve as bio-
markers for ARDS risk. Whole blood offers advantages for miRNA profiling compared
to other tissue types because it contains rich immune cell- and tissue-specific miRNAs
with low risk of noise from additional serum or plasma isolation steps or sample con-
tamination [12]. Therefore, we compared miRNA expression in whole blood prepara-
tions from two large populations of ARDS patients and critically ill at-risk controls.
Methods
Study population and design
This nested case-control study was part of an ongoing Molecular Epidemiology Study
of ARDS (MEARDS) at Harvard Medical School that was initiated in 2000. MEARDS
has more than 4000 patients and includes both ARDS patients and at-risk controls who
were critically ill patients admitted to the ICU of Massachusetts General Hospital
(MGH; Boston, MA) or Beth Israel Deaconess Medical Center (BIDMC; Boston, MA)
[13, 14]. Commonly known ARDS risk factors and their definitions are listed in Add-
itional file 1: Table S1. Detailed inclusion criteria are described in the “Supplemental
Methods and Results” section in Additional file 1 and illustrated in Additional file 1:
Figure S1. All ARDS subjects met the Berlin diagnostic definition [15]: timing of ARDS
was within 1 week of a known clinical insult or new or worsening respiratory symp-
toms; chest imaging showed bilateral opacities (not fully explained by effusions, lobar/
lung collapse, or nodules); respiratory failure was not fully explained by cardiac failure
or fluid overload; and ARDS severity was based on PaO2/FiO2 ratio. Exclusion criteria
included ages younger than 18 years old, diffused alveolar hemorrhage or chronic lung
disease, which may mimic ARDS, and directive to withhold intubation. Patients with
neutropenia not secondary to sepsis and immunosuppression secondary to medication
or diseases such as HIV infection were excluded. Treatment with granulocyte colony-
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stimulating factor or inhibitors of tumor necrosis factor was also excluded [13]. Pa-
tients were enrolled in the study immediately after meeting all inclusion criteria [15].
Institutional review boards of MGH, BIDMC, and Harvard T.H. Chan School of Public
Health approved this study.
We used a two-phase study with a total of 530 participants (recruited during 2003–
2012), including 199 ARDS and 330 at-risk controls. One patient without information
was excluded (Fig. 1). The discovery population (n = 156) included 78 ARDS patients
(cases) and 78 at-risk patients (controls), matched by age (± 5 years) and sex. Twenty-
two miRNAs were used to build an ARDS risk factor panel that included one inde-
pendent validation cohort (n = 373) containing 121 ARDS cases and 252 controls.
RNA isolation
Peripheral whole blood from 530 participants was collected in Tri Reagent solution
(Molecular Research Center, Cincinnati, OH) within 24 h of participant enrollment and
stored at − 80 °C. Tri Reagent is a robust miRNA stabilization method for long-term
storage and can generate reproducible results without degradation [16]. Total RNA
containing small RNA was extracted from whole blood. RNA quality was assessed on
an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), and RNA integrity
numbers (RIN) were reported. Total RNA with RIN of 6.5–10 was processed for com-
plementary DNA synthesis using TaqMan Megaplex RT primer pools A or B and then
Fig. 1 Study design of discovery cohort, validation cohort, and gene set enrichment analysis (GSEA). *One
control sample was excluded due to few detectable miRNAs. **Discovery cohort ARDS and at-risk controls
were matched by age (± 5 years) and gender
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amplified with Megaplex PreAmp primers (Applied Biosystems, Foster City, CA). One
control sample in the validation cohort was excluded due to few detectable miRNAs.
miRNA profiling
In the discovery phase, we used the TaqMan OpenArray Human MicroRNA Panel (Ap-
plied Biosystems) according to the manufacturer’s instructions and detected expression
of 754 human miRNA transcripts. After quality control screening, we selected 294 miR-
NAs for discovery cohort analysis. Twenty-two miRNAs were selected from the discov-
ery cohort for further validation in an independent validation cohort. In the validation
cohort, we used OpenArray QuantStudio system to customize miRNA expression ar-
rays (Applied Biosystems). Technical consistency of assays within and across cohorts
was also tested using three random samples.
Statistical analysis
We applied stringent quality control (QC) criteria for miRNA analysis in order to
maintain the confidence of statistical results: good amplification score > 1.1, Cq confi-
dence > 0.8, high expression (Ct < 30), and detectable expression in more than half of
the samples. We performed both univariate and multivariate logistic regression to iden-
tify miRNA candidates that were associated with ARDS status. Odds ratios (OR) and
95% confidence intervals (CI) were calculated. Discovery miRNA candidate selection
was based on the following criterion: fold change > 1.5 or < 0.67 from the logistic re-
gression model in at least one of four normalization methods [9]. Gene set enrichment
analysis (GSEA) was used to investigate if candidate miRNAs were significantly
enriched in the whole miRNA gene set [17].
To build the miRNA risk factor model, we used miRNAs that were validated in all
cohorts with the same effect directions, and we computed sensitivity, specificity, accur-
acy, and area-under-the-receiver operating characteristic-curve (AUC) to assess per-
formance of risk factors. To compare miRNA risk factors, we considered the base
model for ARDS risk factor assessment to include only Lung Injury Prediction Score
(LIPS) [18]. Based on our miRNA results, we included miR-181a, miR-92a, and miR-
424, in combination with the LIPS model, in a miRNA classifier for ARDS risk factor
evaluation. To further assess the incremental diagnostic power of those three miRNAs
when added to the baseline LIPS risk model, we computed integrated discrimination
improvement (IDI) and net reclassification index (NRI) (“Supplemental Methods and
Results” section in Additional file 1), which offer an intuitive way of quantifying im-
provement offered by new biomarkers [19].
Values of p < 0.05 or false discovery rate (FDR) q < 0.05 were considered significant.
All analyses were performed with R software (v.3.3.0) and Statistical Analysis System
software (v.9.3, SAS Institute).
Results
Demographic features and clinical variables of the discovery and validation cohorts are
presented in Additional file 1: Table S2. In all experiments, we distributed samples such
that age, sex, case-control status, and RNA quality were balanced with respect to the
day of purification and the day of analysis or plate number and were randomized within
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each day and plate. This aspect is important to reduce confounding effects from tech-
nical variation, such as plate-to-plate variation and purification differences [20].
miRNA screening and validation
In total, 754 miRNA transcripts were identified from the discovery cohort. We only in-
cluded 294 miRNAs that met our QC inclusion criteria to maintain robust statistical
results. Ultimately, 22 miRNAs were selected based on fold change as candidate risk
factors for ARDS from the logistic regression model (Table 1). Of the 22 miRNAs, 3
miRNAs—miR-181a, miR-92a, and miR-424—remained significant risk factors (OR >
1.0) or protective factors (OR < 1.0) for ARDS in the validation cohort after multiple
testing adjustment by FDR (Benjamini–Hochberg) (Table 1). From fixed effect meta-
analysis, 14 miRNAs appeared to be significant risk/protective factors for ARDS. Of
those 14 miRNAs, miR-181a, miR-92a, and miR-424 demonstrated the strongest associ-
ations with ARDS risk (p < 0.001) (Table 1).
miR-181a, miR-92a, and miR-424 were the three most significant miRNAs among all
22 miRNAs from the discovery cohort and remained significant in the validation cohort
and meta-analysis. Indeed, under the null hypothesis GSEA [17], miR-181a, miR-92a,
Table 1 miRNA associations with ARDS in discovery cohort, validation cohorts, combined cohorts,
and meta-analysis
Discovery cohort (n = 156) Validation cohort (n = 373) Meta-analysis (n = 529)
MicroRNA OR (95% CI) OR (95% CI) FDR q OR (95% CI) p
miR-424 0.52 (0.29–0.93) 0.78 (0.66–0.94) 0.022 0.77 (0.67–0.9) < 0.001
miR-92a 1.60 (1.11–2.31) 1.75 (1.26–2.43) 0.022 1.69 (1.32–2.17) < 0.001
miR-181a 1.75 (1.03–2.97) 1.76 (1.21–2.56) 0.037 1.68 (1.26–2.23) < 0.001
miR-331 1.67 (1.11–2.52) 1.69 (1.12–2.56) 0.097 1.74 (1.29–2.36) < 0.001
miR-29b 0.66 (0.44–0.99) 0.82 (0.68–0.99) 0.132 0.79 (0.67–0.93) 0.004
miR-1290 0.66 (0.41–1.08) 0.84 (0.72–0.98) 0.097 0.83 (0.73–0.95) 0.006
miR-155 1.57 (1.03–2.38) 1.40 (0.95–2.08) 0.195 1.32 (1.07–1.64) 0.009
miR-148a 0.64 (0.42–0.98) 0.92 (0.7–1.22) 0.511 0.78 (0.62–0.97) 0.023
miR-579 0.57 (0.33–0.97) 0.89 (0.71–1.11) 0.511 0.82 (0.69–0.97) 0.023
miR-1291 0.58 (0.39–0.85) 0.90 (0.73–1.11) 0.511 0.81 (0.68–0.98) 0.027
miR-744* 0.58 (0.38–0.88) 0.89 (0.7–1.13) 0.511 0.82 (0.68–0.99) 0.036
miR-1244 0.64 (0.43–0.95) 0.90 (0.74–1.08) 0.511 0.84 (0.72–0.99) 0.042
miR-486-3p 1.57 (1.02–2.4) 1.12 (0.82–1.53) 0.723 1.28 (1.01–1.63) 0.043
miR-642 1.50 (1.03–2.09) 1.07 (0.88–1.32) 0.723 1.18 (1–1.38) 0.047
miR-340 0.65 (0.44–0.95) 0.93 (0.76–1.15) 0.598 0.87 (0.75–1) 0.057
miR-20a 0.65 (0.43–0.98) 1.02 (0.74–1.41) 0.896 0.87 (0.76–1.01) 0.059
miR-21 0.66 (0.44–0.98) 0.98 (0.76–1.26) 0.723 0.87 (0.74–1.01) 0.067
miR-34a 0.53 (0.31–0.91) 0.95 (0.76–1.2) 0.598 0.85 (0.68–1.05) 0.132
miR-590-3P 0.57 (0.36–0.91) 1.00 (0.87–1.15) 0.896 0.91 (0.81–1.04) 0.165
miR-204 1.57 (1.03–2.38) 0.89 (0.71–1.12) 0.857 1.07 (0.89–1.28) 0.477
miR-493 0.63 (0.39–0.99) 1.16 (0.97–1.39) 0.511 1.03 (0.89–1.2) 0.662
miR-483-5p 0.56 (0.33–0.93) 1.17 (0.98–1.4) 0.481 1 (0.86–1.16) 0.997
Discovery screening based on OR > 1.5 or OR < 0.67. Meta-analysis was conducted based on fixed effect model
OR odds ratio, CI confidence interval, FDR false discovery rate
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and miR-424 were significantly overrepresented and enriched among the top six genes
on a global miRNA scale (Table 2, Additional file 1: Figure S4).
Sepsis and pneumonia stratification analysis
Sepsis and pneumonia are the two most common ARDS-predisposing clinical risks and
account for the highest percentage of risk in our study cohort. Thus, stratification by
sepsis and pneumonia can help validate biomarkers in different risk aspects [21]. Ac-
cording to the risk factor assessment from the validation cohort in Table 3, we selected
six miRNAs that showed significant associations with ARDS and performed stratifica-
tion analyses according to those with sepsis or pneumonia. Among patients with sepsis
or pneumonia, miR-424, miR-92a, and miR-181a remained significantly associated with
ARDS, reinforcing that the association was independent of sepsis or pneumonia.
miRNA diagnostic performance
Including only ARDS patients from the validation cohort, we performed receiver oper-
ating characteristic (ROC) analyses for risk evaluation of ARDS with the LIPS model
(AUC = 0.708; 95% CI 0.651–0.766), sepsis (AUC = 0.572; 95% CI 0.573–0.607), and
pneumonia (AUC = 0.695; 95% CI 0.651–0.740). AUC values of miR-181a, miR-92a,
and miR-424 were larger than that of sepsis, but smaller than AUC values for LIPS or
Table 2 Gene set enrichment analysis of 22 candidate miRNAs in whole miRNA set
MicroRNA Rank in gene list Enrichment score Core enrichment
miR-424 0 0.654 Yes
miR-181a 1 0.560 Yes
miR-1291 2 0.545 Yes
miR-744* 3 0.545 Yes
miR-331 5 0.513 Yes
miR-92a 6 0.480 Yes
miR-1244 7 0.446 Yes
miR-486-3p 8 0.383 Yes
miR-493 11 0.328 Yes
miR-204 13 0.323 Yes
miR-34a 18 0.298 Yes
miR-642 21 0.282 Yes
miR-29b 22 0.281 Yes
miR-483-5p 24 0.278 Yes
miR-340 28 0.259 Yes
miR-148a 29 0.257 Yes
miR-590-3P 33 0.253 Yes
miR-1290 47 0.211 No
miR-21 52 0.203 No
miR-579 76 0.151 No
miR-20a 86 0.138 No
miR-155 211 0.051 No
Seventeen of them found to be significantly overrepresented (FDR q < 0.001) in ARDS vs at-risk control. miR-181a, miR-
92a, and miR-424 are among the top enrich score miRNAs
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pneumonia. Importantly, specificity and accuracy of the three miRNAs were all larger
than those from LIPS, sepsis, or pneumonia (Additional file 1: Table S4), suggesting
that these miRNAs have better performance in correctly classifying at-risk controls.
Addition of any one of the three miRNAs significantly increased baseline LIPS AUC,
sensitivity, specificity, and accuracy (Table 4). When miR-181a, miR-92a, and miR-424
were computed together with the baseline LIPS model, AUC significantly increased to
0.723 (95% CI 0.667–0.778; p = 0.005) (Table 4). Computation of all six miRNAs (miR-
181a, miR-92a, miR-424, miR-1290, miR-29b, and miR-331) together with the baseline
LIPS model further increased AUC to 0.728 (95% CI 0.674–0.783; p = 0.001) (Table 4).
These observations suggest that measurement of three miRNAs (miR-181a, miR-92a,
and miR-424) from whole blood greatly increased the risk evaluation of ARDS in this
population, including AUC, sensitivity, specificity, and accuracy.
Relative IDI values for miR-181a, miR92a, and miR-424 were 1.36 (95% CI 0.14–2.58;
p = 0.029), 1.22 (95% CI 0.09–2.35; p = 0.034), and 1.43 (95% CI 0.12–2.74; p = 0.033),
respectively. Of note, combination of miR-181a, miR-92a, and miR-424 increased IDI
to 2.40 (95% CI 0.72–4.08; p = 0.005) and category-free NRI to 27.21% (95% CI 5.72–
48.70; p = 0.014) (Table 4).
Table 3 Stratification analysis of miRNA associations with ARDS in validation cohorts
Sepsis miR-424 miR-92a miR-181a
N OR (95% CI) p OR (95% CI) p OR (95% CI) p
At-risk control 197 Ref. Ref. Ref.
ARDS 112 0.78 (0.66–0.94) 0.007 1.75 (1.26–2.43) < 0.001 1.76 (1.21–2.56) 0.003
Pneumonia miR-424 miR-92a miR-181a
N OR (95% CI) p OR (95% CI) p OR (95% CI) p
At-risk control 114 Ref. Ref. Ref.
ARDS 102 0.74 (0.6–0.92) 0.007 1.56 (1.05–2.32) 0.029 1.59 (1.03–2.46) 0.035
Stratify on sepsis or pneumonia only. All models were adjusted for age and gender
OR odds ratio, CI confidence interval
Table 4 Diagnostic performance of sepsis/pneumonia model and miRNA combined model for
ARDS
Combined
cohort
(N = 373)
ARDS vs. at-risk controls
AUC (95% CI) Sensitivity, % Specificity, % Accuracy, % IDI (95%
CI)
p Category-free
NRI, % (95% CI)
p
LIPS model 0.708
(0.651–0.766)
64.35 50.81 56.85 Ref. Ref.
miR-181a
+ LIPS
0.719
(0.661–0.776)
65.03 56.82 59.48 1.36
(0.14–2.58)
0.029 15.24
(−6.38–36.87)
0.649
miR-92a
+ LIPS
0.716
(0.659–0.773)
64.85 56.73 59.37 1.22
(0.09–2.35)
0.034 8.96
(−12.69–30.61)
0.418
miR-424
+ LIPS
0.715
(0.659–0.771)
64.78 56.69 59.32 1.43
(0.12–2.74)
0.033 24.24
(2.71–45.76)
0.237
Extended
model 1a
0.723
(0.667–0.778)
65.31 56.96 59.67 2.40
(0.72–4.08)
0.005 27.21
(5.72–48.70)
0.014
Extended
model 2b
0.728
(0.674–0.783)
65.70 57.14 59.92 3.18
(1.28–5.09)
0.001 36.93
(15.58–58.28)
<0.001
AUC area under the curve, IDI integrated discrimination improvement, NRI net reclassification index, LIPS Lung Injury
Prediction Score
aExtend model 1: LIPS + miR-181a + miR-92a + miR-424
bExtend model 2: LIPS + miR-181a + miR-92a + miR-424 + miR-1290 + miR-29b + miR-331
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Discussion
ARDS is a life-threatening inflammatory disease of the lung. Although a mechanical
ventilation strategy has been shown to influence mortality in this syndrome, there is
currently no proven pharmacologic treatment despite more than 30 completed or on-
going clinical trials. The mortality rate of ARDS remains high [1, 22, 23]; therefore,
early diagnosis and prevention are essential. The LIPS model has been used to detect
potential risk factors for ARDS, using clinical predisposing conditions based on clinical
observations. While this method is appropriately sensitive, it may not accurately reflect
the pathophysiological process of ARDS [18].
To our knowledge, this study is the first to use whole blood samples from a large
population of ARDS patients and critically ill, at-risk controls and to use a discovery
and independent validation cohort study design with rigorous statistical analysis of a
high-throughput miRNA set. The primary selected 22 miRNAs from the discovery co-
hort were further validated in an independent cohort and with subsequent meta-
analysis. Such diligent analyses may offer an advantage for miRNA profiling and greatly
reduce risk of misrepresentation from miRNA expression noise that typically results
from additional serum or plasma isolation steps and sample contamination. Although
patient collection spanned 10 years, we carefully selected high-quality samples and con-
trolled all experiments by grouping patients into a randomly selected discovery cohort
and a validation cohort according to dates of sample collection. We used identical
amounts of RNA input in all experiments to control against bias caused by variation
due to different RNA input amounts. We also distributed samples such that age, sex,
case-control status, and RNA quality were balanced with respect to the day of purifica-
tion and the day of analysis or plate number and randomized within each day and plate
to reduce confounding factors from technical variation, such as plate-to-plate variation
and purification differences.
miRNAs have been used successfully as biomarkers for chronic diseases, such as pan-
creatic and gastric cancers [9, 24]. This study identified three promising miRNAs—-
miR-181a, miR-92a, and miR-424—that are associated with human ARDS. GSEA
confirmed that they were significantly overrepresented in ARDS cases compared to
controls in these study cohorts, although there is no evidence directly linking these
miRNAs to ARDS. However, multiple recent studies provide indirect evidence for the
miRNAs’ involvement in dysregulated ARDS signaling pathways [25–27].
Here, we report that miR-181a and miR-92a are associated with ARDS risk in all
tested cohorts and meta-analysis. These findings are consistent with prior studies in in-
flammation and endothelial cell injury, which are common in ARDS [28]. miR-181a is a
key regulator of T-cell development and T-cell receptor signaling threshold [25]. In-
creased miR-181a expression in mature T-cells augments cell sensitivity to peptide anti-
gens. Further, T-cell responses decline with age due to an age-associated defect in T-
cell receptor signaling, which is caused by increased expression of phosphatase 6 and
miR-181a. The miR-181 family is also upregulated in asthma airway inflammation [29]
and neutrophil regulation [30], which both play crucial roles in the pathophysiology of
ARDS [2].
miR-92a inhibits endothelial cell angiogenesis and impairs endothelial cell function
[26, 31–33]. miR-92a also targets Krüppel-like factor 2 (KLF2), KLF4, and sirtuin 1,
thereby promoting inflammatory responses [26, 33, 34]. Further, lung microvascular
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endothelium injury-associated pulmonary edema is a hallmark of ARDS [35, 36]. When
miR-92a is overexpressed, blood vessel growth and functional recovery of damaged tis-
sue are restricted [31], which may enhance the incidence of pulmonary edema and
ARDS.
In contrast, miR-424 was a protective factor for ARDS in our study (Table 1). miR-
424 is downregulated in pulmonary artery hypertension (PAH) via apelin and fibroblast
growth factor 2 signaling in pulmonary artery endothelial cells [27]. PAH is commonly
observed in ARDS patients, who can have hypoxemia that promotes pulmonary vaso-
constriction to give rise to PAH. Hypoxia-induced miR-424 plays an important role in
vascular remodeling and angiogenesis in endothelial cells [37]. Low oxygen levels affect
cells and tissues during wound healing as well as during pathological conditions, such
as stroke. As a consequence, miR-424 signaling is activated in endothelial cells to
stabilize hypoxia-inducible factors [37]. These prior studies support our finding that
miR-424 expression may exert a protective effect against ARDS.
Of note, sepsis and pneumonia had lower prevalence in at-risk controls than ARDS
subjects in this population. Thus, we conducted stratification analysis to prove that the
top three miRNAs (miR-181a, miR-92a, and miR-424) remained significantly associated
with ARDS regardless of sepsis and pneumonia imbalance between our two cohorts.
LIPS is currently considered a standard clinical prediction model and is associated with
ARDS risk and complications [18]. A recent study evaluating LIPS on ARDS develop-
ment showed LIPS has an AUC of 0.70 [38], which is consistent with our results [38].
All three miRNAs selected from our two cohorts had similar specificity and accuracy in
predicting ARDS to that of LIPS. Further, incorporation of these miRNAs with LIPS
further increased the potency and accuracy of ARDS risk estimate. Therefore, miRNAs
identified from this study may have incremental utility to that of LIPS for future ARDS
risk evaluation.
This study focused mainly on three miRNAs selected from the validation cohort.
However, that does not mean that the remaining 19 miRNAs identified in the discovery
cohort are irrelevant. Some of these miRNAs have been implicated in inflammatory sig-
naling pathways and may also be ARDS candidate risk factors. For example, miR-155
and miR-21 are functionally related and contribute to NF-κB signaling [39], an import-
ant pathway for innate and adaptive immunity and inflammation. miR-155 is also up-
regulated in asthma, and the miR-29 family is upregulated in adult lungs. Further, miR-
21 has been shown to play multiple roles in different pulmonary diseases, such as idio-
pathic pulmonary fibrosis and pulmonary arterial hypertension, by targeting several im-
mune receptors and cytokines, including IL-12 and SMAD7 [29]. Further investigation
is needed to inform the involvement of these miRNAs in ARDS, which might provide a
better understanding of mechanisms underlying the disease.
The miRNAs identified for ARDS risk were different from the ones we identified in
previous prior study [11]. ARDS patients have a rapid change in the syndrome progress,
from the initial pulmonary tissue damage and inflammation/infection to later wherein
some of them developed MOF. And miRNAs are functional. This fact explains why
miRNAs signal can be different under various disease biological conditions even with
the same phenotype. The miRNAs we found in the other study were mainly associated
with organ failure, whereas the miRNAs in current study were mainly associated with
endothelial cell damage and inflammatory response.
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However, we also acknowledge limitations of our study. First of all, our results were
only based on 294 (out of 754) miRNAs that passed stringent QC criteria. It is possible
that miRNAs did not pass QC are functionally related to ARDS. More studies, such as
miRNA injection in ARDS mouse model, are needed to proof their functionality. The
diagnostic power of our miRNAs might not be sufficiently strong. However, unlike
other similar studies [8, 24], our control subjects were at-risk patients who share more
features with ARDS cases, which may have reduced confounding variables compared to
the use of healthy controls. In addition, ARDS is considered a complicated syndrome
with multiple etiologies, so a single or a few miRNAs might not show strong signals for
all ARDS patients. This concept was recently confirmed in an ARDS randomized clin-
ical trial, which concluded that aspirin has no beneficial effect for ARDS prevention
[40]. Aspirin has direct effect only on platelet function-related mechanistic pathways
[41]. Although alteration in platelet function was found during ARDS development
[42], it was not the only mechanistic pathway. Also, our study was based on a single
geographic region—a geographically different, external cohort in a similar study setting
would be helpful to further validate our findings. In this study, miRNA target gene ex-
pression data are not available. Future research on such targets will be informative for
validating the functions of the identified miRNA in ARDS and provide more compre-
hensive understanding of mechanistic knowledge.
Conclusions
This study links whole blood expression of miR-181a, miR-92a, and miR-424 to
ARDS. Inflammatory response markers miR-181a and miR-92a were significantly el-
evated in ARDS patients, while pulmonary artery endothelial cell anti-inflammation
marker miR-424 was significantly reduced in ARDS patients. Further, expression
patterns of our miRNA biomarkers may provide an in-depth molecular understand-
ing of ARDS among at-risk patients beyond clinical factors, such as sepsis and
pneumonia. In addition, combining these miRNA biomarkers with the LIPS model
may further improve ARDS diagnosis.
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